Clinical Trials Directory

Trials / Terminated

TerminatedNCT01056757

Treatment With Ribavirin for Patients With Metastatic Breast Cancer

A Phase I/II Exploratory Study of Ribavirin in Metastatic Breast Cancer Expressing Elevated eIF4E

Status
Terminated
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
4 (actual)
Sponsor
Jewish General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to learn whether oral Ribavirin is safe and effective in treating patients with metastatic breast cancer, that have high levels of eIF4E.

Detailed description

Overexpression of eIF4E occurs in greater than 50% of BC, where it has been associated with clinical progression, angiogenesis and chemoresistance. eIF4E protein expression is not elevated in stroma or in benign tissue. A major focus in the future management of BC is to develop novel targeted therapeutics, with associated biomarkers of clinical value. It is possible that targeting a central regulator that can control multiple pathways might be more effective than targeting a single downstream molecule. In our preclinical studies, we have demonstrated that ribavirin inhibits proliferation of BC cell lines at clinically achievable concentrations by inhibiting its target, eIF4E. This trial addresses the important clinical issue of the lack of treatment for poor prognosis BC, characterized by overexpression of eIF4E. We will explore the use of eIF4E as therapeutic target and a predictive marker. We will determine whether targeting eIF4E with ribavirin, a commercially approved, inexpensive, oral therapeutic compound with a favourable toxicity profile, may present a novel treatment option for patients with aggressive, metastatic disease.

Conditions

Interventions

TypeNameDescription
DRUGRibavirin1000 mg bid, po, q28days

Timeline

Start date
2009-12-01
Primary completion
2010-11-01
Completion
2010-11-01
First posted
2010-01-26
Last updated
2015-11-04

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01056757. Inclusion in this directory is not an endorsement.